VNRX

Volition is a pre-commercial epigenetics diagnostics company whose numbers describe a business running on fumes. FY2025 revenue was just $1.73M (up 40%, but off a trivial base), against a $23.4M net loss and $21.7M operating loss — an operating margin of roughly -1,259%. Five years of history show revenue crawling from $90K to $1.73M while cumulative losses piled the accumulated deficit to -$253M. This is not a company with a durability or margin story; it is a research program that has yet to prove a market.

The balance sheet is the disqualifier. Cash and equivalents fell 65.8% to $1.12M, while operating cash burn was $19.7M for the year — on that run-rate the company has only weeks of self-funded runway. Stockholders' equity is negative at -$34.2M against $42.5M of liabilities, current liabilities ($12.2M) dwarf current assets ($2.06M), and debt (the Lind Notes) is growing. Management's own filing is explicit: the auditors issued a going-concern opinion, and survival depends on 'obtaining additional financing through debt or equity transactions,' grant funding, or licensing. Shares already ballooned 64.2% in a single year, so equity holders face near-certain, heavy dilution just to keep the lights on — and 'we could be forced to cease operations' if capital isn't raised.